Haleon plc (NYSE:HLN) Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC raised its holdings in Haleon plc (NYSE:HLN) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 85,690 shares of the company’s stock after acquiring an additional 2,101 shares during the period. Sequoia Financial Advisors LLC’s holdings in Haleon were worth $814,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in HLN. Sierra Ocean LLC acquired a new stake in shares of Haleon during the 4th quarter worth approximately $26,000. Versant Capital Management Inc increased its holdings in shares of Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Haleon during the 4th quarter worth approximately $35,000. Toronto Dominion Bank increased its holdings in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Haleon during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN stock opened at $10.16 on Monday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The stock has a market capitalization of $45.97 billion, a PE ratio of 29.87, a P/E/G ratio of 2.82 and a beta of 0.25. The firm has a 50 day moving average of $9.75 and a two-hundred day moving average of $9.87.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. On average, research analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a $0.1166 dividend. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on HLN shares. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Finally, HSBC reaffirmed a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.